In Europe young patients with Graves’ disease are usually treated with antithyroid drugs initially, then if hyperthyroidism recurs after a prolonged course of such medication, they are offered definitive treatment by subtotal or total thyroidectomy. Neither of these forms of treatment is free from problems. Impressed with the simplicity and safety record of radioiodine therapy, we have treated 8 young patients with radioiodine. The patients all presented with typical Graves’ disease and relapsed after 18–24 months of treatment with antithyroid drugs. They were then given the option of a further course of antithyroid medication or definitive treatment with radioiodine or surgery. Those who opted for radioiodine were treated with 131iodine in a dose of 300 MBq with the intention of ablating the thyroid. Antithyroid medication was resumed for 4–6 months and then withdrawn. Four patients became hypothyroid after a single dose of radioiodine but 4 needed a second dose. All became hypothyroid within 2 years. No adverse effects were observed, in particular no patient showed any deterioration in their eye disease. Radioiodine offers a simple, effective and inexpensive method of treatment for Graves’ disease in young patients. There are no immediate adverse effects and, although some theoretical concerns remain, to date the long-term safety record of thyroid ablation is excellent and the potential risks seem to us to be outweighed by the advantages. Even when a moderately high initial dose of radioiodine is used, a second dose may be needed.

1.
Perrild H, Grüters-Kieslich A, Feldt-Rasmussen U, Grant D, Martino E, Kayser L, Delange F: Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol 1994;131:467–473.
2.
Safa AM, Schumacher P, Rodriguez-Antunez A: Long-term follw-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med 1975;292:167–171.
3.
Freitas JE, Swanson DP, Gross MD, Sisson JC: Iodine-131: Optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med 1979;20:847–850.
4.
Hamburger JI: Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985;60:1019–1024.
5.
Franklyn JA: The management of hyperthyroidism. N Engl J Med 1975;330:1731–1738.
6.
Baxter MA, Stewart PM, Daykin J, Sheppard MC, Franklyn JA: Radioiodine therapy for hyperthyroidism in young patients: Perception of risk and use. Q J Med 1993;86:495–499.
7.
Macdougall IR: Which therapy for Graves’ hyperthyroidism in children? Nucl Med Commun 1989;10:855–857.
8.
Administration of Radioactive Substances Advisory Committee: Notes for Guidance on the Administration of Radioactive Substances to Persons for Purposes of Diagnosis, Treatment or Research. London, Department of Health, 1993.
9.
National Radiological Protection Board: Guidance Notes for the Protection of Persons against Ionising Radiations Arising from Medical and Dental Use. Department of Health and Social Services, Northern Ireland, Scottish Home and Health Department, Welsh Office, 1988, pp 57–59.
10.
Franklyn JA, Daykin J, Droic Z, Farmer M, Sheppard MC: Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol 1991;34:71–76.
11.
Rudberg C, Johansson H, Åkerström G, Tuvemo T, Karlsson FA: Graves’ disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol 1996;134:710–715.
12.
Miccoli P, Vitti Rago T, et al: Surgical treatment of Graves’ disease: Subtotal or total thyroidectomy? Surgery 1996;120:1020–1025.
13.
Hedley AJ, Young RE, Jones SJ, Alexander WD, Bewsher PD, Scottish Automated Follow-Up Register Group: Antithyroid drugs in the treatment of hyperthyroidism of Graves’ disease: Long-term follow-up of 434 patients. Clin Endocrinol 1989;31:209–218.
14.
Winsa B, Dahlberg PA, Jansson R, Ågren H, Karlsson FA: Prognostic factors in Graves’ disease. Acta Endocrinol 1990;122:722–728.
15.
Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM: Treatment of Graves’ disease with the block-replace regimen of antithyroid drugs: The effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med 1994;87:337–341.
16.
Reinwein D, Benker G, Lazarus JH, Alexander WD, the European Multicenter Study Group on Antithyroid Drug Treatment: A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. J Clin Endocrinol Metab 1993;76:1516–1521.
17.
Lippe BM, Landaw EM, Kaplan SA: Hyperthyroidism in children treated with long term medical therapy: Twenty-five percent remission every two years. J Clin Endocrinol Metab 1987;64:1241–1245.
18.
Glaser NS, Styne DM: Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997;82:1710–1726.
19.
Feldt-Rasmussen U, Schleusener H, Carayon P: Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves’ disease. J Clin Endocrinol Metab 1994;78:98–102.
20.
Kawai K, Tamai H, Matsubayashi S, Mukata T, Morita T, Kubo C, Kuma K: A study of untreated Graves’ patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs. Clin Endocrinol 1995;43:551–556.
21.
Notsu K, Oka N, Masaki Y, Furuya H, Kato Y: Plasma free triiodothyronine response to thyrotropin-releasing hormone to predict the remission of Graves’ disease treated with antithyroid drugs. J Clin Endocrinol Metab 1991;73:396–400.
22.
Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T: Administration of thyroxine in treated Graves’ disease. Effects on the levels on antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991;324:947–953.
23.
Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S: Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves’ disease patients. J Clin Endocrinol Metab 1995;80:1481–1484.
24.
McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A: Lack of effect of thyroxine in patients with Graves’ hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996;334:220–224.
25.
Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: A report of the Cooperative Thyrotoxicosis Therapy Follow-Up Study. J Clin Endocrinol Metab 1974;38:976–978.
26.
Holm L-E, Hall P, Wiklund K, Lundell G, Berg G, Bjelkengren G, Cederquist E, Ericsson U-B, Hallquist A, Larsson L-G, Lidberg M, Lindberg S, Tennvall J, Wicklund H, Boice JD: Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst 1991;83:1072–1077.
27.
Hall P, Boice JD, Berg G, Bjelkengren G, Ericsson U-B, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, Wiklund K, Holm L-E: Leukaemia incidence after iodine-131 exposure. Lancet 1992;340:1–4.
28.
Brincker H, Hansen HS, Andersen AP: The induction of leukaemia by 131I treatment of thyroid carcinoma. Br J Cancer 1973;28:232–237.
29.
Edmonds CJ, Smith T: The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 1986;59:45–51.
30.
Sarker SD, Beierwaltes WH, Gill SP, Cowley BJ: Subsequent fertility and birth histories of children treated with 131I for thyroid cancer. J Nucl Med 1976;17:460–464.
31.
Hardisty CA, Jones SJ, Hedley AJ, Munro DS, Bewsher PD, Weir RD: Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism. J R Coll Physicians Lond 1990;24:36–42.
32.
Kendall-Taylor P, Keir MJ, Ross WM: Ablative radioiodine therapy for hyperthyroidism: Long-term follow-up. Br Med J 1984;289:361–363.
33.
Nikiforov Y, Gnepp DR, Fagin JA: Thyroid lesions in children and adolescents after the Chernobyl disaster: Implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab 1996;81:9–14.
34.
Williams D: Editorial: Thyroid cancer and the Chernobyl accident. J Clin Endocrinol Metab 1996;81:6–8.
35.
Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A: Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. N Engl J Med 1992;326:1733–1738.
36.
DeGroot LJ, Gorman CA, Pinchera A, Bartalena L, Marocci C, Wiersinga WM, Prummel MF, Wartofsky L: Therapeutic controversies. Radiation and Graves’ ophthalmopathy. J Clin Endocrinol Metab 1995;80:339–349.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.